EGFR and non-small cell lung carcinoma: The previous comparisons revealed two main differences in the basic clinical characteristics of patients with de novo vs. secondary metastatic EGFR+ NSCLC: frequency of brain and other extrathoracic metastases, as well as ECOG PS at diagnosis of stage IV disease (Table 1 and Supplementary Table 1).